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Abstract
Purpose The aim of this study was to explore the cerebral
distribution of the tau-specific PET tracer [18F]THK5317 (al-
so known as (S)-[18F]THK5117) retention in different stages
of Alzheimer’s disease; and study any associations with
markers of hypometabolism and amyloid-beta deposition.
Methods Thirty-three individuals were enrolled, including
nine patients with Alzheimer’s disease dementia, thirteen with
mild cognitive impairment (MCI), two with non-Alzheimer’s
disease dementia, and nine healthy controls (five young and four
elderly). In a multi-tracer PET design [18F]THK5317, [11C]
Pittsburgh compound B ([11C]PIB), and [18F]FDG were used
to assess tau pathology, amyloid-beta deposition and cerebral
glucose metabolism, respectively. TheMCI patients were further
divided into MCI [11C]PIB-positive (n=11) and MCI [11C]PIB-
negative (n=2) groups.
Results Test-retest variability for [18F]THK5317-PET was
very low (1.17–3.81 %), as shown by retesting five patients.
The patients with prodromal (MCI [11C]PIB-positive) and
dementia-stage Alzheimer’s disease had significantly higher
[18F]THK5317 retention than healthy controls (p=0.002 and
p=0.001, respectively) in areas exceeding limbic regions, and
their discrimination from this control group (using the area
under the curve) was >98 %. Focal negative correlations be-
tween [18F]THK5317 retention and [18F]FDG uptake were
observed mainly in the frontal cortex, and focal positive cor-
relations were found between [18F]THK5317 and [11C]PIB
retentions isocortically. One patient with corticobasal degen-
eration syndrome and one with progressive supranuclear palsy
showed no [11C]PIB but high [18F]THK5317 retentions with a
different regional distribution from that in Alzheimer’s disease
patients.
Conclusions The tau-specific PET tracer [18F]THK5317
images in vivo the expected regional distribution of tau
pathology. This distribution contrasts with the different
pa t terns of hypometabol i sm and amyloid-beta
deposition.
Keywords Positron emission tomography . Alzheimer’s
disease . Tau . Neurofibrillary tangles . THK5317 . Other
dementia . Non-AD . Amyloid PET . FDG . PIB
Introduction
Alzheimer’s disease (AD) in vivo diagnosis has been
reconceptualised since the introduction of amyloid-beta-
specific PET tracers. Amyloid-beta accumulation becomes
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apparent early in the asymptomatic stage of the disease [1],
however, it reaches a plateau when the first symptoms occur
[2], preventing further monitoring of the disease progression.
Abnormal tau hyperphosphorylation and deposition also start
early [3] but are known to better relate to disease severity and
cognitive decline [4], and represent, thus, an attractive marker
for assessing the temporal evolution of the disease.
The wide spectrum of degenerative tauopathies includes
AD, corticobasal degeneration, progressive supranuclear pal-
sy etc. Those diseases are associated with different isoforms of
tau protein as well as different regional distribution of the
underlying pathology [5]. Therefore, PET imaging of the load
and regional distribution of tau pathology in vivo constitutes a
great challenge for the research on neurodegenerative diseases.
Several families of promising tau-specific tracers have
been developed during the last years, with few in-vivo reports
published [6–8]. Among these tracers, THK5117 has shown
high affinity for and selective binding to tau pathology [9, 10],
and its S-form enantiomer (also known as [18F]THK5317)
showed favourable pharmacokinetics [11]. However, there re-
mains a paucity of evidence regarding imaging tau pathology
in different stages of AD as well as other tauopathies.
Until recently, the study of the regional distribution of tau
pathology in relation to amyloid-beta deposition and neurode-
generation was only possible post-mortem. However,
post-mortem studies are limited to a single time point, most
often at the end stage of the disease, and provide only a weak
link between the individual’s ante-mortem clinical profile and
the underlying pathology. The combination of imaging
markers for amyloid-beta and cerebral metabolism with the
newly developed tau tracers is opening exciting new opportu-
nities for the in-vivo research of AD and other tauopathies.
The aims of this study were two-fold: 1) using
[18F]THK5317-PET, to evaluate the presence and regional
distribution of tau pathology in vivo in a cohort of AD pa-
tients; and 2) to examine the regional distribution of tau pa-
thology in relation to hypometabolism and amyloid-beta de-
position in vivo.
Methods
Study population
The 33 enrolled individuals included nine patients diagnosed
with AD (57–75 years old), 13 with mild cognitive impair-
ment (MCI) (59–79 years old), four age-matched elderly
healthy controls (eHC; 58–71 years old) and five young
healthy controls (yHC; 20–30 years old). Two patients with
non-AD dementia were also recruited, in an exploratory man-
ner, including one with a clinical diagnosis of corticobasal
degeneration and one with progressive supranuclear palsy.
All patients were referred to the Memory Clinic at the
Department of Geriatric Medicine, Karolinska University
Hospital, Stockholm, Sweden, and underwent thorough clin-
ical investigation including medical history, physical exami-
nation, laboratory blood tests, Apolipoprotein E (ApoE)
genotyping, neuropsychological assessment, cerebrospinal
fluid sampling and MRI scans. The diagnosis was based on
the consensus of a committee, which included geriatricians,
neurologists, clinical neuropsychologists, and specialist
nurses.
All AD patients fulfilled the National Institute of
Neurological and Communication Disorders, Alzheimer’s
Disease and Related Disorders Association criteria [12] and
the DSM-IV criteria for Dementia of the Alzheimer’s type
[13], while all MCI patients met the Petersen criteria [14].
Eleven MCI patients were classified as amnestic
single-domain, and two as amnestic multi-domain [15]. All
amnestic single-domain MCI patients were classified as MCI
PIB-positive (n=11) based on their amyloid status, as deter-
mined by their [11C]Pittsburgh compound B (PIB) PET scan
(see the B[11C]PIB- and [18F]FDG-PET image pre-
processing^ section below), while the amnestic multi-
domain MCI patients were classified as MCI PIB-negative
(n = 2). For the purposes of this project, all MCI PIB-
positive patients were reclassified into a prodromal AD group
in accordance with the new research diagnostic criteria [16].
Similarly, all PIB-positive patients with clinically diagnosed
ADwere reclassified into the AD dementia group. This result-
ed in eleven patients with prodromal AD, nine with AD de-
mentia and two with MCI PIB-negative.
The two patients with non-AD dementia were clinically
diagnosed as follows: one patient with predominantly
left-sided signs of atypical parkinsonism, progressive apraxia
and executive deficits fulfilled the criteria for possible
corticobasal degeneration syndrome [17], and one patient with
progressive postural instability and falls, vertical supranuclear
opthalmoparesis, dysdiadochokinesia and executive defi-
cits fulfilled the criteria for probable progressive
supranuclear palsy [18].
Nine individuals (five yHC and four eHC) were recruited
as healthy controls either via Clinical Trial Consultants AB
(Uppsala University Hospital, Uppsala, Sweden) or from pa-
tients’ familial circles, after extensive clinical evaluation.
They were included in the absence of cognitive complaint,
prior head injury, or known neurologic/psychiatric disorder.
They were all non-smokers and free from medication.
Neuropsychological assessment
All individuals completed a large battery of neuropsycholog-
ical tests. Individual performances (except mini mental state
examination (MMSE) performance) are expressed as z-scores,
from comparison with a reference group of healthy controls
[19].
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Global cognition was assessed as the average performance
in nine tests, including five subtests from the Weschler Adult
Intelligence Scale (i.e. Similarities, Information, Block Design,
Digit Span, and Digit Symbol), the Corsi test, the Trail-Making
Tests A and B, and the Rey-Osterrieth complex figure copy test.
Episodic memory was assessed as the average performance in
the following three tests: the Rey-Auditory Verbal Learning
learning and 30 min delayed-retention tests, and the
Rey-Osterrieth complex figure retention subtest.
Image acquisition
A PETscan using [18F]THK5317 and a 3D-T1-weightedMRI
sequence were acquired for all participants. Additionally, all
participants except the yHC group underwent a [11C]PIB-PET
scan, and all patients (i.e. those with prodromal AD, AD de-
mentia, MCI PIB-negative, and non-AD dementia) underwent
an [18F]FDG-PET scan.
The [18F]THK5317- and [11C]PIB-PET scans were ac-
quired on an ECAT EXACT HR+ scanner (Siemens/CTI) or
a Discovery ST PET/CT scanner (GE) at the Uppsala PET
centre, Uppsala, Sweden. Both tracers were synthesised ac-
cording to standard good manufacturing processes as previ-
ously described [11, 20]. For [18F]THK5317-PET, 22 frames
were acquired over 60min (6×10 s, 3×20 s, 2×30 s, 2×60 s,
2 × 150 s, 4x300 s, and 3x600 s frames) after intravenous
injection of 212±42MBq. For [11C]PIB-PET, 24 frames were
acquired over 60 min (4 × 30s, 9 × 60 s, 3 × 180 s and
8×300 s) after intravenous injection of 253±69 MBq. The
[18F]FDG-PETscans were acquired on a Biograph mCT PET/
CTscanner (Siemens) at the Department of Nuclear Medicine,
Karolinska University Hospital Huddinge, Stockholm,
Sweden, with a 15 min static run, 30 min after injection
(30–45min) of 3MBq/kg. All acquisitions were reconstructed
using ordered subset expectation maximisation.
[18F]THK5317-PET image pre-processing
All T1-weighted MRI images were divided into grey and
white matter (GM and WM, respectively) tissue classes using
SPM8 software’s unified segmentation. The inverse non-
linear transformation from this segmentation step was used
to wrap a probabilistic atlas [21] from MNI space into each
individual’s native T1 space. The resulting individual atlases
were subsequently multiplied using the corresponding
binarised probabilistic GM mask, to obtain individual GM
atlases. In addition to 30 bilateral regions of interest (ROI)
in the probabilistic atlas, two composite bilateral GM ROIs
were created, according to the classical neuropathological
staging of tau pathology [22]: a limbic ROI (Braak stages
III–IV) comprising the following regions: hippocampi, amyg-
dalas, and parahippocampal, fusiform, middle inferior tempo-
ral, orbital and straight frontal gyri, as well as temporal poles
and parietal-temporal-occipital junctions; and an isocortical
ROI (Braak stages V–VI), comprising all isocortical regions
except the precentral and postcentral gyri.
Individual dynamic [18F]THK5317-PET images were co-
registered onto the individual T1-weighted image with PMOD
v.3.5 software (PMOD Technologies Ltd., Adliswil,
Switzerland). In order to create distribution volume ratio
(DVR) images, the reference Logan graphical method was
applied to the [18F]THK5317 images over the 30–60min scan
interval, with cerebellar GM—extracted from the T1 segmen-
tation—as a reference, as previously described [11].
Additional [18F]THK5317 preprocessing methods
Standard uptake value (SUV) images (40–60 min) were also
created for [18F]THK5317. The SUV was defined as the ra-
dioactivity concentration (MBq/mL) divided by [injected dose
(MBq)/ patient’s weight (kg)]. Standard uptake value ratio
(SUVR) images, using cerebellar GM—extracted from the
T1 segmentation—as a reference, were generated for all indi-
viduals. Additional SUV images were used to assess the pa-
tient with progressive supranuclear palsy, since the latter dis-
ease is characterised by the presence of tau pathology in the
cerebellum [23].
The [18F]THK5317 dynamic images were also analysed,
using the Muller-Gartner partial volume correction method as
implemented in PMOD v.3.5 software, based on the individ-
ual T1-weighted images.
[11C]PIB- and [18F]FDG-PET image pre-processing
[11C]PIB-PET (40–60 min) and [18F]FDG-PET (30–45 min)
images were created and co-registered onto the individual
T1-weighted images using SPM8. SUVR images were created
using the cerebellar GM as reference for [11C]PIB and the
pons for [18F]FDG scans. An SUVR threshold of 1.41 for
amyloid positivity was applied to [11C]PIB-PET data [24].
Additional DVR images for [11C]PIB retention were generat-
ed using the reference Logan graphical method over the 30–
60-min scan interval, with cerebellar GM as a reference, as
previously described for [18F]THK5317 DVR.
Test-retest
Five patients (four with prodromal AD and one with
corticobasal degeneration) underwent a second PETscan with
[18F]THK5317 on a separate day, not more than 37 days from
the first. DVR images were created as previously described.
Statistical analysis— ROI-based comparisons
Differences between all healthy controls (i.e. yHC and eHC),
prodromal, and dementia-stage AD for continuous variables
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were assessed with the non-parametric Kruskal–Wallis
one-way analysis of variance (ANOVA), with post-hoc
Mann–Whitney Bonferroni-corrected pairwise comparisons;
medians and interquartile ranges (IQR) are reported. In detail,
to assess comparisons across the three diagnostic groups in the
two composite ROIs (limbic and isocortical), Bonferroni-
corrected alpha levels of 0.008 were applied (0.05/6 [3 groups
× 2 ROIs]). Fisher’s exact tests were used to assess differences
between groups for discrete variables.
Within-individual test-retest variability was assessed using
the relative difference [(Retest-Test)/Test] in retention be-
tween scans in ROIs from the probabilistic atlas. The
intraclass correlation coefficient, a measure of reproducibility
was applied.
In order to determine which ROIs from the probabilistic
atlas were best for discriminating between AD patients (i.e.
patients with prodromal and AD dementia) and all healthy
controls (i.e. yHC and eHC), receiver operating characteristic
(ROC) analysis was performed and the area under the curve
(AUC) was determined for each ROI.
All the above-mentioned statistical comparisons were carried
out using SPSS v.22.0 software (Armonk, NY: IBM Corp) for
Mac OS X. Graphical representations were carried out with the
ggplot2 package v.1.0.1 as implemented in R v.3.1.3 software.
Correlation matrices—incorporating the Pearson coeffi-
cient—were created to evaluate, two by two, the cortical ROI-
based relationships between [18F]THK5317 DVR retention and
[18F]FDG SUVR uptake, using the Hmisc v.3.14 and corrplot
v.0.73 packages as implemented in R v.3.1.3 software.
Statistical analysis— Voxel-based comparisons
Comparisons of [18F]THK5317 DVR retention among all
healthy controls (i.e. yHC and eHC), prodromal AD, and
AD dementia patients at the voxel-level were assessed, two
by two, using a non-parametric alternative to two-sample
T-tests. Due to the limited sample sizes of each diagnostic
group significant differences were assessed with a standard
non-parametric procedure based on permutation testing, as
implemented in the statistical non-parametric mapping tool-
box (SnPM13) [25]. [18F]THK5317 DVR images were regis-
tered into the MNI space using the corresponding transforma-
tion matrix obtained at the T1 segmentation step, and were
smoothed (FWHM = 8 mm in all directions) using SPM8.
Statistical significance was assessed with permutation tests
with 10,000 permutations corrected for multiple comparisons
using the false discovery rate test (p<0.05).
Individual retention in patients was also compared with the
mean retention in the healthy controls with the creation of
individual z-score maps. For [18F]THK5317, mean and stan-
dard deviation images were created from the DVR images
from the five yHCs. A z-score threshold of 1.96 (95 % confi-
dence interval) was used to determine areas of abnormally
h igh [18F]THK5317 re ten t ion (z-scores > 1 .96) .
[18F]THK5317 DVR images from each patient were binarised
according to the threshold, and were consequently summed in
order to illustrate the areas of abnormally high retention in
each diagnostic group (Online Resource 1).
Relationships between tracers with respect to retention at
the voxel-level were assessed, two by two, with the BPM
(Biological Parametric Mapping) 3.1 toolbox [26], using the
individual PET images registered into the MNI space and
smoothed, as discussed above.A cluster threshold of 20 voxels
was applied, with no correction for multiple comparisons
(p < 0.001). Two more lenient thresholds (p < 0.01 and
p<0.05) were also applied to acknowledge the limited sample
size.
The results of the voxel-based comparisons were projected
onto either the individual or the group average cortical sur-
faces using Freesurfer 5.3 (http://surfer.nmr.mgh.harvard.
edu/).
Results
Study population
The characteristics of the study population are summarised in
Table 1. There were no statistically significant differences be-
tween prodromal AD and AD dementia groups with regard to
age or gender. Patients with prodromal AD and AD dementia
only differed significantly with respect to their neuropsycho-
logical assessment; patients with dementia scored lower on the
MMSE test and the composite measure of episodic memory
than the prodromal patients.
Test-retest
There was low within-individual variability in the
[18F]THK5317 DVR values (Table 2). The mean absolute
relative difference ranged from 1.17 to 3.29 % for the
isocortical ROIs and from 1.51 to 3.81 % for the subcortical
ROIs. The intraclass correlation coefficient ranged from 0.86
to 0.98 for the isocortical ROIs and from 0.94 to 0.98 for the
subcortical ROIs, with only the posterior cingulate cortex
resulting in a coefficient of 0.52.
[18F]THK5317 retention and regional distribution in AD
[18F]THK5317 retention was high in both prodromal and AD
dementia patients in isocortical and subcortical regions, in direct
contrast to the lack of retention in the yHC group (Fig. 1).
[18F]FDG uptake was low in isocortical areas in AD patients,
with more pronounced changes in the dementia group.
The composite limbic and isocortical [18F]THK5317
(DVR, SUVR) retention across the diagnostic groups is
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illustrated in Fig. 2a. There was no overlap in [18F]THK5317
DVR retention between AD dementia patients and all healthy
controls (i.e. yHC and eHC), and almost no overlap between
prodromal AD patients and healthy controls. No significant
differences in [18F]THK5317 retention were observed be-
tween prodromal and AD dementia patients. A similar pattern
of [18F]THK5317 retention, but with a wider range and greater
overlap between diagnostic groups, was observed when using
SUVR quantification (Figs. 1, and 2a).
Good discrimination between the different diagnostic
groups was seen in most ROIs (Online Resource 2).
Discrimination between all AD patients (i.e. patients with pro-
dromal and AD dementia) and all healthy controls (i.e. yHC
and eHC) was best in the composite limbic ROI, the
isocortical ROI, and the temporal cortex, with AUC values
of 0.994, 0.983, and 0.978, respectively, followed by the oc-
cipital (0.958), parietal (0.944), and frontal (0.872) cortices
(Fig. 2b). In the subcortical ROIs, the AUC in the putamen
reached 0.853.
Voxel-based comparisons between all healthy controls (i.e.
yHC and eHC) and patients with prodromal as well as AD
dementia revealed widespread neocortical areas with in-
creased [18F]THK5317 retention in both patient groups
(Fig. 2c), including predominantly the inferior and lateral tem-
poral, anterior frontal, lateral occipital, and inferior parietal
cortices, as well as the precuneus. No significant difference
was observed in [18F]THK5317 retention between prodromal
and AD dementia patients across the neocortex.
In comparison to the yHC group only, [18F]THK5317 re-
tention was higher in the AD patients in areas similar to the
ones mentioned above (Fig. 3a–b). The primary motor, so-
matosensory, and superior temporal cortices appeared to be
spared from high [18F]THK5317 retention. Although a similar
pattern of [18F]THK5317 retention was observed in the pa-
tients with prodromal and AD dementia, abnormally high
[18F]THK5317 retention in the lateral temporal, lateral occip-
ital, and parietal regions was observed in greater proportion in
AD dementia patients. Of note, similar findings were found to
a large extent when using the eHC group as a reference
(Online Resource 3).
Correlations between the regional distributions
of the different tracers
Across all AD patients (n=20), at a voxel level, significant
negative correlations between [18F]THK5317 DVR retention
Table 1 Demographic and clinical characteristics of the study population
yHC eHC MCI PIB-positive
(Prodromal AD)
AD dementia PSP CBD MCI PIB-negative
n 5 4 11 9 1 1 2
Age, years 22 [22:28] 62 [60.3:65] 73 [65:74] 67 [60:74] 66 69 64 ; 79
Gender (male/female) 0/5 3/1 5/6 2/7 1/0 1/0 1/1
ApoE ε4 frequency n/a n/a 6 (60 %)† 7 (78 %) 0 (0 %) n/a 0 (0 %)†
Education, years 15 [14.3:17] 14 [12.5:15.5] 12 [10:14] 14 [12:15] 9 15 8 ; 18
MMSE n/a n/a 29 [27.5:29.5] a 24 [23:25] 24 23 23 ; 27
Global cognition, z-scores 0.9 [0.9:1.2] −0.6 [−1.1:0.0] −0.5 [−0.8:0.2] −2.5 [−6.3:0.3] b −3.3 −3.3 −1.0 ; −1.5
Episodic memory, z-scores 1.0 [0.7:1.2] −0.7 [−1.2:0.7] −1.5 [−1.9:0.1] a −2.6 [−2.8:-2.0] b n/a −2.0 −1.0 ; −0.9
Time
PIB to THK5317, days
n/a 0 [0–2] 0 [0–4] 0 [0–7] 0 9 0 ; 0
Time
FDG to THK5317, days
n/a n/a 56 [38:84] 60 [41:64] 106 92 101 ; 620
Time
CSF to THK5317, days
n/a n/a 745 [492:993] 857 [391:1888] 103 694 558 ; 636
CSFAβ1–42, pg/mL n/a n/a 547 [506.3:851]
§ 484.5 [449.8:526.5]† 693 1700 607 ; 792
CSF t-tau, pg/mL n/a n/a 465 [301:492]
‡ 546 [368:675.8]† 239 644 210 ; 933
CSF p-tau181p, pg/mL n/a n/a 62.5 [49.8:86.5]
§ 82 [57:104.3]† 36 98 36 ; 120
Significant differences with a Bonferroni-corrected threshold of p< 0.016 for pair-wise comparisons a relative to patients with AD dementia; b relative to
all HC (i.e. yHC and eHC)
Data are presented as medians [Interquartile range], or as n(%). Aβ amyloid-beta, AD Alzheimer’s disease, ApoE apolipoprotein E, CBD corticobasal
degeneration, eHC elderly healthy controls, FDG [18 F]FDG, MMSE mini mental state examination, n/a results not available, PIB [11 C]Pittsburgh
compound B, MCI PIB-positive/negative mild cognitive impairment with [11 C]PIB uptake above/below the normal range (threshold standard uptake
value ratio of 1.41), PSP progressive supranuclear palsy, THK5317 [18 F]THK5317, yHC young healthy controls
† data missing for one individual
‡ data missing for three individuals
§ data missing for four individuals
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Table 2 Test (T)-retest (R) comparison for [18F]THK5317 DVR regional values in five patients
Individual Region of Interest
Frontal
cx
Temporal
cx
Parietal
cx
Occipital
cx
Insular
cx
Anterior
cingulate
gyrus
Posterior
cingulate
gyrus
Hippocampus Putamen Caudate
nucleus
Thalamus
Prodromal AD no 1 – T 1.20 1.16 1.06 1.08 1.29 1.24 1.25 1.32 1.67 1.08 1.34
Prodromal AD no 1 – R 1.20 1.14 1.05 1.08 1.26 1.22 1.25 1.30 1.66 1.08 1.35
% Difference −0.47 −1.81 −0.93 0.18 −2.03 −1.16 0.31 −1.26 −0.26 0.41 1.04
Prodromal AD no 2 – T 1.13 1.11 1.10 1.20 1.22 1.23 1.21 1.30 1.46 0.89 1.27
Prodromal AD no 2 – R 1.15 1.13 1.09 1.16 1.20 1.26 1.26 1.37 1.51 1.05 1.34
% Difference 2.29 1.74 −0.39 −2.91 −2.30 2.79 4.21 5.36 2.93 18.92 5.38
Prodromal AD no 3 – T 1.24 1.14 1.06 1.17 1.31 1.23 1.23 1.44 1.63 1.31 1.42
Prodromal AD no 3 – R 1.24 1.15 1.05 1.18 1.32 1.28 1.29 1.48 1.62 1.39 1.48
% Difference −0.20 0.71 −0.59 0.81 1.17 3.68 4.80 3.02 −0.70 5.72 4.43
Prodromal AD no 4 – T 1.17 1.08 1.11 1.10 1.26 1.25 1.28 1.33 1.59 1.00 1.38
Prodromal AD no 4 – R 1.19 1.10 1.11 1.11 1.29 1.25 1.25 1.30 1.63 0.99 1.38
% Difference 1.98 1.42 0.05 0.27 2.86 0.52 −1.84 −2.65 2.07 −0.58 −0.04
CBD – T 1.09 1.10 1.05 1.08 1.23 1.14 1.21 1.19 1.79 0.74 1.20
CBD – R 1.08 1.06 1.01 1.03 1.24 1.11 1.15 1.11 1.76 0.74 1.18
% Difference −1.07 −3.45 −3.90 −3.98 0.36 −2.29 −5.28 −6.75 −1.58 −0.70 −1.81
Mean absolute, %
Difference
1.20 1.83 1.17 1.63 1.74 2.09 3.29 3.81 1.51 5.27 2.54
Standard deviation 0.91 1.00 1.56 1.71 0.98 1.27 2.12 2.21 1.07 7.96 2.27
Intraclass correlation
coefficient
0.98 0.86 0.90 0.95 0.90 0.93 0.52 0.94 0.98 0.97 0.95
ADAlzheimer’s disease, cx cortex,CBD corticobasal degeneration, cx cortex,Prodromal ADmild cognitive impairment with [11 C]PIB uptake above the
normal range (threshold standard uptake value ratio of 1.41); % Difference: [(R-T)/T]; Intraclass correlation coefficient: [(BIMSS−WIMSS)/(BIMSS +
WIMSS)], where BIMSS = between-individuals mean sum of squares, andWIMSS = within-individual mean sum of squares. Frontal, temporal, parietal
and occipital cortices were defined according to the Hammers’ probabilistic atlas [21]
Fig. 1 Sample [18F]THK5317
DVR, and [18F]THK5317,
[18F]FDG and [11C]PIB SUVR
images from a young healthy
control (yHC), and patients with
prodromal and dementia-stage
Alzheimer’s disease (AD).
DVR= distribution volume ratio;
PIB = [11C]PIB; Prodromal
AD=mild cognitive impairment
(MCI) with [11C]PIB retention
above the normal range (threshold
standard uptake value ratio of
1.41); R =Right;
SUVR= standard uptake value
ratio
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Fig. 2 [18F]THK5317 retention in and discrimination ability between
healthy controls and patients with Alzheimer’s disease (AD). The
boxplots represent [18F]THK5317 DVR and SUVR retention across
diagnostic groups in the composite limbic and isocortical regions of
interest (ROIs) (a). The color-coding represents the area under the curve
(AUC) of the individual cortical ROIs for discrimination between
all healthy controls (i.e. yHC and eHC) and all AD patients (i.e.
prodromal and dementia-stage) (b). Voxel-based comparisons of
[18F]THK5317 DVR retention (SnPM) among all healthy controls (i.e.
yHC and eHC), prodromal AD, andADdementia patients after correction
for multiple comparisons with the use of the false discovery rate test
(p< 0.05) (c). The threshold for [11C]PIB positivity = 1.41. Filled dots
represent outliers and individuals belonging to the MCI [11C]PIB-nega-
tive and non AD groups; eHC= elderly healthy controls; PIB= [11C]PIB;
Prodromal AD=mild cognitive impairment (MCI) with [11C]PIB reten-
tion above the normal range (threshold standard uptake value ratio of
1.41); non AD = non-AD dementia; yHC = young healthy controls;
n/a = not available; * p< 0.05
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and [18F]FDG SUVR uptake were observed in focal areas of
the prefrontal cortex and the lateral and mesial parietal cortices
unilaterally (p<0.001) (Fig. 4a, Online Resource 4). More
liberal thresholds for significance (p<0.01 and p<0.05) re-
vealed more extensive bilateral areas of the same regions as
well as significant correlations in the lateral temporal cortex.
Positive correlations (p<0.001) between the two tracers were
observed bilaterally in the superior temporal (max T=9.9),
occipital (max T=7.7), and primary motor (max T=8.9) cor-
tices. In the ROI-based comparisons only negative
correlations were observed between the regional retention of
the two tracers; predominantly in the frontal cortex (Online
Resource 5).
[18F]THK5317 DVR retention positively correlated with
[11C]PIB SUVR retention (p<0.001) bilaterally, in the mesial
and inferior temporal, anterior and superior frontal, lateral and
mesial parietal, and occipital cortices (Fig. 4b, Online
Resource 6). More liberal thresholds for significance
(p<0.01 and p<0.05) detected more extensive areas of the
same regions. A similar pattern of positive correlations were
Fig. 3 Regional patterns of abnormal [18F]THK5317 retention across all
patients with prodromal Alzheimer’s disease (AD) (n = 11) and AD
dementia (n = 9). Individual [18F]THK5317 DVR images were
compared to those from the five young healthy controls using z-score
maps. Only voxels with z-score values above 1.96 (95 % confidence
interval) were considered. The resulting individual binarised images
were summed to illustrate the areas of abnormal retention in the two
diagnostic groups (Online Resource 1). DVR = distribution volume
ratio; PIB = [11C]PIB; SUVR= standard uptake value ratio
Fig. 4 Correlations between tracers, two by two, across all Alzheimer’s
disease patients (n = 20). Voxel-based negative correlations between
[18F]THK5317 DVR retention and [18F]FDG SUVR uptake (a).
Voxel-based positive correlations between [18F]THK5317 DVR and
[11C]PIB SUVR retention (b). Three thresholds for statistical significance
were applied (p< 0.001, p< 0.01, and p< 0.05) as indicated. The peak
voxels of clusters meeting the p < 0.001 threshold are detailed in Online
Resource 4 and 6. DVR= distribution volume ratio; SUVR= standard
uptake value ratio
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observed between [18F]THK5317 DVR with [11C]PIB DVR
retention (Online Resource 7). No significant negative corre-
lations (p<0.001) were observed between the two tracers.
Elderly healthy controls
All the eHCs were found to be amyloid negative, according to
their [11C]PIB-PET scans. Incidental MRI findings included
one eHC with mesial temporal atrophy (score 1–2 out of 4)
(Online Resource 8c) and one eHC with parietal atrophy
(score 1–2 out of 3) (Online Resource 8d). Overall, the
eHCs exhibited low [18F]THK5317 retention although, at an
individual level, focal areas of high retention were observed in
mesial areas of the frontal, temporal, and parietal cortices, in
comparison to yHCs (Online Resource 8).
Regional distribution of tau pathology in other
tauopathies
The two patients with non-AD dementia were found to be
amyloid-negative based on their isocortical [11C]PIB
retention.
The patient with the clinical diagnosis of possible
corticobasal degeneration syndrome showed widespread high
[18F]THK5317 retention predominantly in WM areas, the basal
ganglia and theWM of the cerebellum (Fig. 5a). Low [18F]FDG
uptake, predominantly in the right hemisphere, was reported
from clinical visual assessment in the parietal and prefrontal
cortices, with asymmetrical uptake in the thalami. Parietal atro-
phy (score 1 out of 3) was observed bilaterally in the T1MRI of
the patient with a light rightward asymmetry.
The patient with the clinical diagnosis of probable pro-
gressive supranuclear palsy showed high [18F]THK5317
DVR retention only in the basal ganglia and the midbrain
bilaterally (Fig. 5b). SUV images were created to control
for possible cerebellar [18F]THK5317 retention. Areas of
high [18F]THK5317 SUV retention were detected in wide-
spread isocortical areas, as well as the basal ganglia, the
brainstem and the cerebellum (Fig. 6). Areas of low
[18F]FDG uptake in the insula, anterior cingulate cortex
as well as the basal ganglia and thalami were clinically
reported. Global cortical atrophy (score 1–2 out of 3) was
observed on the T1 MRI of the patient.
The twoMCI PIB-negative patients exhibited different pat-
terns of high [18F]THK5317 retention. The first patient, a male
with signs of atypical parkinsonism, progressive executive
and memory deficits, showed high [18F]THK5317 retention
predominantly in the mesial parietal cortex, the basal ganglia,
and focal changes in the WM of the cerebellum, in compari-
son to yHC (Fig. 5c). The same patient showed a strongly
leftward asymmetrical cortical pattern of low [18F]FDG up-
take with accompanying low uptake in the basal ganglia and
thalami. Global cortical atrophy (score 2 out of 3) and mesial
temporal atrophy (score 3 [right] and 4 [left] out of 4) were
observed on the T1 MRI of the patient. In the other MCI
PIB-negative patient, a female with progressive executive
Fig. 5 [18F]THK5317 DVR retention, [18F]THK5317 DVR z-score
maps in comparison to young healthy controls (left two columns),
[18F]FDG SUVR uptake (third column) and T1 MRI (fourth column) in
the patients with non-Alzheimer’s disease dementia (first two rows) and
the MCI PIB-negative patients (last two rows). A z-score threshold of
1.96 (95 % confidence interval) was applied. CBD = corticobasal
degeneration; DVR= distribution volume ratio; MCI PIB-negative =mild
cognitive impairment (MCI) with [11C]PIB uptake below the normal
range (threshold standard uptake value ratio of 1.41); PIB = [11C]PIB;
PSP= progressive supranuclear palsy; R =Right; SUVR= standard up-
take value ratio
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deficits including word-finding difficulties, although average
isocortical bilateral [11C]PIB retention was below the
1.41 SUVR threshold, areas of abnormally high retention
were observed isocortically. Strongly asymmetrical high
[18F]THK5317 retention was observed in the left fronto-
parieto-temporal hemisphere of this patient in comparison to
yHC. No areas of low [18F]FDG uptake or atrophy were clin-
ically reported in this patient (Fig. 5d).
Partial volume correction
Partial volume correction was used to account for the WM re-
tention of [18F]THK5317, and the resulting spill-over fromWM
to GM. This resulted in a wider range of DVR values in all
ROIs; e.g. in the isocortical ROI, DVR retention ranged from
1.12 to 1.71 after correction, while it ranged from 1.03 to 1.37
without correction. Most comparisons were not affected by the
correction. However, the differences between all healthy con-
trols and AD patients were greater after correction of the
[18F]THK5317 data than before correction in ROIs prone to
WM spill-over. These regions included the hippocampus, ante-
rior cingulate, and superior temporal ROIs. The results of these
comparisons are illustrated in Online Resource 9.
Discussion
Imaging of in-vivo tau pathology will both shed new light on
whether it is tau or amyloid pathologies that drive the cascade of
events leading to AD, and serve as a tool for studying the pro-
gression of the disease. The key strength of this study was the
use of [18F]THK5317, a tau-specific PET tracer with well-
characterised kinetic properties [11] in a cohort of patients at
different stages of AD, as well as the use of different quantifica-
tion methods. Themultimodal study of tau pathology, in relation
to glucose metabolism ([18F]FDG) and amyloid-beta deposition
([11C]PIB), provides a suitable design for exploring the regional
and temporal evolution of the underlying pathologies in AD.
Test-retest reproducibility
The test-retest reproducibility was very high and the within-
individual variability was low in the procedures using
[18F]THK5317. The poor test-retest reproducibility in the pos-
terior cingulate gyrus (0.52), despite the low within-individual
variability (3.29 %), can be explained by the low retention
variability in that ROI among the patients that underwent
test-retest investigation, which negatively biased the measures
of reproducibility [27].
Fig. 6 [18F]THK5317 SUV retention in a representative young healthy
control (yHC) and a patient with progressive supranuclear palsy (PSP)
(upper two rows), [18F]THK5317 SUV z-score map in comparison to
yHCs for the PSP patient (last row). A z-score threshold of 1.96
(95 % confidence interval) was applied. R = Right; SUV = standard
uptake value as the radioactivity concentration (MBq/mL) divided by
[injected dose (MBq)/ patient’s weight (kg)].
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[18F]THK5317 retention in AD
The high [18F]THK5317 retention in the AD patients and the
low retention in the healthy controls resulted in excellent dis-
crimination between the groups in regions associated with the
accumulation of tau pathology in AD. More specifically, the
ranking of areas that discriminated best between all healthy
controls and patients with AD strongly resembles the stereo-
typical pattern of the temporal spreading of tau pathology [22,
28].
Patients with prodromal AD or AD dementia in our study
exhibited a regional distribution of abnormally high
[18F]THK5317 retention that spread isocortically beyond the
limbic areas [22], with no statistical significant difference ob-
served in [18F]THK5317 retention between the two patient
groups. It seems possible, therefore, that the isocortical prop-
agation of tau pathology precedes the dementia-stage of the
disease. Nevertheless, the AD dementia patients showed, in
greater proportion than prodromal patients, abnormal
[18F]THK5317 retention in areas that are expected to be af-
fected late by tau pathology [22, 28]. The recruitment of main-
ly mild dementia patients in our study could preclude more
extensive differences in [18F]THK5317 retention between
prodromal and dementia patients.
Striatal [18F]THK5317 retention was observed in all clini-
cal groups, including healthy controls, in accordance with
post-mortem data [10]. This has also been reported with other
newly developed tau tracers [29, 30] and is presently a source
of discussion. However, in light of the good discrimination
between controls and AD patients using [18F]THK5317 reten-
tion in the putamen, and despite the moderate non-specific
retention in this region in the yHC group, it could conceivably
be hypothesised that [18F]THK5317 is able to successfully
detect underlying tau pathology in this region [31].
Glucose metabolism and amyloid-beta deposition
in relation to [18F]THK5317 retention
There was a negative regional correlation between [18F]FDG
uptake and [18F]THK5317 retention in AD patients, although
this was restricted to focal areas of the prefrontal cortex and the
precuneus, suggesting that the first signs of hypometabolism
occur when the tau pathology has already extended beyond the
limbic region and has spread isocortically. Surprisingly, we also
observed a few positive correlations in the voxel-wise compar-
isons in the isocortical areas spared from hypometabolism even
at the latest stages of AD. This findingmight be due to the use of
different scanners for the two tracers. Indeed, ROI-based com-
parisons, less prone to noise in comparison to voxel-based anal-
ysis, identified only negative correlations between [18F]FDG
uptake and [18F]THK5317 retention; predominantly in the fron-
tal cortex.
Positive correlations were observed between [18F]THK5317
and [11C]PIB retention in these patients, suggesting the possible
temporal proximity of the build-up of the two pathological pro-
cesses (amyloid and tau). Moreover, it is possible that this asso-
ciation, regardless of the different regional distribution of the
pathologies in AD, could partly reflect the co-localisation of
the two hallmarks in neuritic plaques, namely dense amyloid
plaques surrounded by dystrophic neurites often containing tau
pathology [32]. Those significant findings, however, were not
corrected formultiple comparisons and further studies need to be
carried out in order to address our statistical power issues and
validate our results. An additional uncontrolled factor is the pos-
sibility that the newly developed tau-specific PET tracers bind to
amyloid deposits with lower affinity than tau fibrils since both
consist of beta-sheet structures of protein aggregates.
[18F]THK5317 retention in other tauopathies
The two patients with non-AD dementia and the twoMCI PIB-
negative patients showed regional [18F]THK5317 retention
that significantly differed from the typical pattern observed in
AD patients. The patient with clinically diagnosed corticobasal
degeneration syndrome exhibited high retention in areas con-
sistent with the reported neuropathological distribution of tau
pathology in this disease [33], similarly to findings reported
with a different tau-specific tracer [29]. The patient with clin-
ically diagnosed progressive supranuclear palsy showed
[18F]THK5317 retention in the expected isocortical and sub-
cortical regions [23]. However, the regional retention patterns
described in these two patients should be interpreted with cau-
tion given the clinical and pathological heterogeneity of these
diseases, as well as the overlaps between them [34, 35].
The cases of non-AD pathology discussed here illustrate
the complexities of tau imaging. Firstly, the clinical syn-
dromes do not correlate well with the neuropathological find-
ings, as discussed above. Secondly, the underlying pathology
could negate the use of the cerebellum or the brainstem as
reference regions. Finally, the involvement of different types
of tau deposits and tau isoforms challenges the interpretation
of the observed findings, since much uncertainty exists re-
garding the form of tau the newly developed tracers target,
and future in-vitro work in pathologically confirmed cases
will be of great importance.
The MCI PIB-negative patient with signs of atypical par-
kinsonism showed a retention pattern similar to that observed
in the non-AD patients. The MCI PIB-negative patient with
progressive executive deficits including word-finding difficul-
ties showed a clearly asymmetrical fronto-parieto-temporal
pattern of [18F]THK5317 retention. Taking the clinical and
imaging profiles together, it could be speculated that this pa-
tient could demonstrate an early syndrome in the spectrum of
primary progressive aphasias [36], although the patient did not
meet the existing criteria at the time of the study [37]. Clinical
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follow-up of these two patients will reveal more information
regarding their underlying pathology.
Tracer characteristics
Several studies have documented that different optical isomers
possess different pharmacological profiles [38] and that it might
be best to use an enantiomerically pure compound as a tracer.
The choice of the S-form enantiomer of the tracer [18F]THK5117
used in this study was based on preliminary findings suggesting
it has faster kinetics and lower non-specific retention than the
racemic mixture (Victor Villemagne, unpublished data). Indeed,
improved pharmacokinetics and a faster dissociation rate from
the WM have already been observed for the S-enantiomers of
two other tracers of the same family [39, 40]. The S-form of the
tracer THK5117 ([18F]THK5317) showed fast kinetics [11] and
lower non-specific retention as visually observed in comparison
to the previous reports on the racemic mixture [9, 39]. For in-
stance, in our study clear discrimination between healthy controls
and patients was observed in the putamen, a region prone to non-
specific spill-over; these results are in contrast to those of an
earlier study that used the racemic form of [18F]THK5117, where
no difference was seen between groups [9].
[18F]THK5317 retention measured as DVR and SUVR dis-
criminated well between all healthy controls and patients with
AD, although the SUVR values showed greater overlap be-
tween groups. Taken together with previous findings indicating
that SUVR values were not particularly accurate for measuring
[18F]THK5317 retention [11], these results suggest that SUVR
retention values should be interpreted with caution.
In order to account for the potential spill-over of
[18F]THK5317 retention from WM to GM, and for the atro-
phy observed in the brains of patients with AD, additional
analyses were carried out with partial volume correction.
This resulted in roughly similar discrimination between the
groups in the majority of regions. Nonetheless, after correc-
tion, better discrimination between groups was revealed in the
hippocampus and anterior cingulate gyrus. This finding has
important implications for future studies aiming to investigate
[18F]THK5317 retention in those regions, given their signifi-
cance in the deposition of tau pathology in AD.
Limitations
The small sample size, especially of patients with pathologies
other than AD, limits the generalisability of our findings.
Moreover, only linear relationships between the different pa-
thologies were assessed, although it is likely that non-linear
models would depict best the association between biomarkers.
Lastly, associations between the tracers’ retention were only
assessed in corresponding regions, precluding findings be-
tween remote regions’ retention. These matters deserve to be
addressed in future studies.
Conclusion
This study shows that [18F]THK5317, a tau-specific PET tracer,
can image with a high reproducibility the expected extent and
regional distribution of tau pathology in a cohort of healthy
controls and patients at different clinical stages of AD. These
results indicate that tau pathology, hypometabolism, and
amyloid-beta deposition follow different patterns of regional
and temporal spread. Future studies incorporating cognitive
measures and longitudinal design will provide a better under-
standing of the cascade of events leading to AD.
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